A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Researchers at Stanford have found that nascent polypeptide-associated complex (NAC) and the apical domain of CCT1, as well as peptide fragments and fusion proteins containing them, can be used to suppress pathological protein aggregation.
Stanford researchers have patented protein stability regulation methods using destabilizing domains (DDs) optimized for use in humans. The ability to control specific protein abundance in cells is a powerful tool for gene therapy and investigating biological behavior.
Researchers in Dr. Karl Deisseroth's lab have engineered a channelrhodopsin variant that can be stimulated by red light and has fast stimulation frequencies. In neurons, channelrhodopsins are light activated protein channels that induce action potential firing.
FragFEATURE is a data-driven computational method for fragment binding prediction. It predicts small molecule fragments preferred by a protein structure using a knowledge base of all previously observed protein-fragment interactions.
Druggability of a protein is its potential to be modulated by drug-like molecules. It is important in the target selection phase. We developed DrugFEATURE to quantify druggability by assessing the microenvironments in potential small-molecule binding sites.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Stanford researchers have developed a highly specific, tunable system to improve the safety, efficacy and deliverability of gene therapy vectors and other biological therapies.
Alloreaction-associated antigen (ARAg) is a novel member of the immunoglobulin superfamily. This invention's issued US patent claims composition of matter of ARAg polypeptides and nucleic acids encoding ARAg polypeptides.